Central amino acids mediate cardiovascular response to angiotensin II in the rat

Brain Research Bulletin
D N ZhuT Ogihara

Abstract

To elucidate the role of the rostral ventrolateral medulla (RVLM) in cardiovascular control through the release of central amino acid neurotransmitters, experiments were performed in Sprague-Dawley (normotensive) rats and spontaneously hypertensive rats (SHR) anesthetized with urethane by using microdialysis sampling from the RVLM for determination of amino acid neurotransmitters. The baseline release of the excitatory amino acid neurotransmitter, glutamate (GLU) from the RVLM in SHR was higher and those of the inhibitory amino acid neurotransmitters, glycine (GLY), taurine (TAU), and gamma-aminobutyric acid (GABA), were lower than in normotensive rats. Microinjection of angiotensin II (ANG II) into the RVLM caused a dose-dependent increase in mean arterial pressure (MAP) and heart rate (HR), accompanied by increased release of GLU in the RVLM. In contrast, microinjection of the ANG II type 1 receptor (AT1) antagonist CV 11974 into the RVLM reduced MAP and HR, accompanied by increased release of GLY, TAU and GABA. These changes in MAP and HR after administration of ANG II or AT1 antagonist were partially blocked by the use of the corresponding antagonist of each amino acid neurotransmitter. Furthermore, these effects were more ...Continue Reading

References

Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Mar 19, 1993·Regulatory Peptides·G P AldredF A Mendelsohn
Feb 1, 1996·Hypertension·Y HirookaR A Dampney
Nov 1, 1995·Pharmacology & Toxicology·S HöhleT Unger
Aug 1, 1992·Trends in Endocrinology and Metabolism : TEM·P C WongP B Timmermans

❮ Previous
Next ❯

Citations

Jan 30, 2004·Vascular Pharmacology·Worku Abebe, Mahmood S Mozaffari
May 16, 2002·Clinical and Experimental Pharmacology & Physiology·Colin SumnersMingyan Zhu
May 16, 2002·Clinical and Experimental Pharmacology & Physiology·Alan F SvedYoshiharu Yajima
Jul 10, 2012·Journal of Applied Physiology·Alexander Gabor, Frans H H Leenen
Oct 17, 2012·Amino Acids·Sanya Roysommuti, J Michael Wyss
Apr 20, 2014·American Journal of Hypertension·Frans H H Leenen
Sep 24, 2015·Neuropeptides·Patrícia M FerreiraMaria J Campagnole-Santos
May 29, 2003·British Journal of Pharmacology·Shereeni J Veerasingham, Mohan K Raizada
Dec 12, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·T IshideA Ally
Apr 4, 2015·Current Hypertension Reports·Kristin E Claflin, Justin L Grobe
Mar 31, 2004·Canadian Journal of Physiology and Pharmacology·A T Anitha NandhiniC V Anuradha
Oct 6, 2005·Journal of the Society for Gynecologic Investigation·Mostafa A El-HaddadMichael G Ross
May 27, 2010·Journal of Hypertension·Alain G Dupont, Sofie Brouwers
Feb 14, 2014·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Takeshi Saigusa, Jun Arita
May 20, 2014·American Journal of Physiology. Heart and Circulatory Physiology·Yang-Kai WangWei-Zhong Wang
Nov 14, 2003·Canadian Journal of Physiology and Pharmacology·Worku Abebe, Mahmood S Mozaffari
Feb 24, 2001·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·O BaltatuM Bader

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.